CADL Q3 EPS Estimate Reduced by Brookline Capital Markets

Key Points

• Brookline Capital Markets lowered Candel Therapeutics’ Q3 2026 EPS estimate to a loss of $0.33 per share from $0.26 previously, and forecasts a Q4 loss of $0.32 per share.
• Candel reported a quarterly loss of $0.52 per share, missing the $0.24 consensus estimate by $0.28 and highlighting continued losses and cash-burn risk.
• Despite mixed analyst views, the stock carries a consensus “Moderate Buy” rating with an average price target of $19.29; shares recently opened at $11.72.

Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Equities researchers at Brookline Capital Markets dropped their Q3 2026 EPS estimates for shares of Candel Therapeutics in a note issued to investors on Wednesday, August 12th. Brookline Capital Markets analyst K. Dolliver now forecasts that the company will earn ($0.33) per share for the quarter, down from their prior forecast of ($0.26). The consensus estimate for Candel Therapeutics' current full-year earnings is ($1.03) per share. Brookline Capital Markets also issued estimates for Candel Therapeutics' Q4 2026 earnings at ($0.32) EPS.

Several other research firms have also issued reports on CADL. Cantor Fitzgerald initiated coverage on shares of Candel Therapeutics in a report on Monday, April 20th. They set an "overweight" rating for the company. Bank of America upped their price target on Candel Therapeutics from $9.00 to $12.00 and gave the stock a "neutral" rating in a research note on Friday. Zacks Research raised Candel Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Friday, May 15th. Wall Street Zen cut Candel Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Candel Therapeutics in a report on Friday, July 17th. Seven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Candel Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $19.29.

Candel Therapeutics Stock Performance

NASDAQ:CADL opened at $11.72 on Monday. The firm has a market capitalization of $896.81 million, a P/E ratio of -8.31 and a beta of -0.51. The company has a debt-to-equity ratio of 0.38, a current ratio of 16.09 and a quick ratio of 16.09. Candel Therapeutics has a one year low of $4.35 and a one year high of $11.95. The company's 50-day simple moving average is $9.68 and its 200 day simple moving average is $7.41.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.28).

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets grew its position in Candel Therapeutics by 128.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company's stock worth $40,000 after purchasing an additional 4,439 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Candel Therapeutics by 361.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company's stock valued at $49,000 after buying an additional 7,527 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in shares of Candel Therapeutics during the 4th quarter valued at $51,000. ProShare Advisors LLC bought a new position in shares of Candel Therapeutics during the 4th quarter valued at $59,000. Finally, Invesco Ltd. purchased a new position in shares of Candel Therapeutics in the 1st quarter worth $59,000. Institutional investors own 13.93% of the company's stock.

Insider Activity

In other Candel Therapeutics news, CTO Seshu Tyagarajan sold 7,000 shares of the company's stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $10.02, for a total transaction of $70,140.00. Following the transaction, the chief technology officer owned 83,865 shares in the company, valued at approximately $840,327.30. This represents a 7.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Francesca Barone sold 23,447 shares of the firm's stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $10.06, for a total transaction of $235,876.82. Following the sale, the insider directly owned 77,362 shares in the company, valued at approximately $778,261.72. The trade was a 23.26% decrease in their position. The SEC filing for this sale provides additional information. 14.30% of the stock is currently owned by corporate insiders.

More Candel Therapeutics News

Here are the key news stories impacting Candel Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $23 price target, implying substantial potential upside from recent trading levels. The firm’s outlook reflects expectations for future earnings growth and progress in Candel’s pipeline. HC Wainwright reaffirms Buy rating and price target
• Positive Sentiment: Management highlighted “meaningful execution” toward a biologics license application (BLA) submission in the fourth quarter. Candel is targeting its first commercial product in 2027, making regulatory progress a key catalyst for the stock. CADL rises as biotech targets 2027 commercial launch
• Neutral Sentiment: Bank of America raised its price target from $9 to $12 but maintained a Neutral rating. The revised target is close to the recent share price, suggesting the analyst sees limited near-term upside despite the higher valuation estimate. Bank of America raises CADL price target
• Negative Sentiment: Candel reported a second-quarter loss of $0.52 per share, substantially worse than the $0.27 consensus estimate. The earnings miss highlights continued cash-burn and execution risk for the clinical-stage biotechnology company. Candel second-quarter earnings release
• Negative Sentiment: HC Wainwright modestly reduced its FY2028 and FY2029 EPS estimates to $0.69 and $1.41, respectively. Although the firm retained its Buy rating and $23 target, the estimate cuts indicate slightly lower expectations for Candel’s long-term profitability.

Candel Therapeutics Company Profile

Candel Therapeutics NASDAQ: CADL is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company's lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel's pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source